Xeris Biopharma Holdings, Inc. Company profile
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. It markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for primary periodic paralysis. The company also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was founded in 2005 and is headquartered in Chicago, Illinois.Latest shares articles
![](https://img.capital.com/imgs/articles/384x2000x0/1350x880_-HP-_Newsquawk-light_1.png)
![](https://img.capital.com/imgs/articles/384x2000x0/meta_1.jpeg)
![](https://img.capital.com/imgs/articles/384x2000x0/shutterstock_2035197281_0_0-infy.jpeg)
![](https://img.capital.com/imgs/articles/384x2000x0/tesla_0.jpeg)